computational biology Latest News

Bio-IT World has announced that complimentary keynote and exhibit hall passes are now available for the 2013 Bio-IT World Expo, taking place April 9-11 in Boston, MA.

Genome Designs, genome annotation and metabolic modelling service provider, today announced a partnership with SciDM Group, a bioinformatics tools developer. The company will be using SciDM’s high performance database engine and other technologies.

Dr. Quackenbush will present in the translating biomarker driven cancer treatments into practice session.

CHI’s Integrated R&D Informatics conference will once again be held at the Molecular Med TRI-CON 2012 on Feb. 21-23, 2012 at the Moscone in San Francisco, CA. This conference is part of the many program options available at the Tri-Conference.

Bio-IT World has announced that complimentary keynote and exhibit hall passes are now available for the 2013 Bio-IT World Expo, taking place April 9-11 in Boston, MA.

Presentation download from the Structure-Based Drug Design 2012 conference organized by Cambridge Healthtech Institute & Bio-IT World

Genome Designs, genome annotation and metabolic modelling service provider, today announced a partnership with SciDM Group, a bioinformatics tools developer. The company will be using SciDM’s high performance database engine and other technologies.

Dr. Quackenbush will present in the translating biomarker driven cancer treatments into practice session.

BioDatomics is a software/hardware platform supported by cutting edge data storage & delivery technologies and can deliver all the computational power required for high throughput techniques in the discovery of disease treatment, origin & prevention.

CHI’s Integrated R&D Informatics conference will once again be held at the Molecular Med TRI-CON 2012 on Feb. 21-23, 2012 at the Moscone in San Francisco, CA. This conference is part of the many program options available at the Tri-Conference.

Students encouraged to take minor’s prerequisites now to prepare for fall 2012 launch

Isogenica, Biolauncher and Cresset Biomolecular Discovery forge alliance to bring powerful target-to-drugs platform to market. Joint venture aims to rapidly identify small molecule therapeutics to pharma targets.